10-KPeriod: FY2007

QUEST DIAGNOSTICS INC Annual Report, Year Ended Dec 31, 2007

Filed February 22, 2008For Securities:DGX

Summary

Quest Diagnostics Incorporated, a leader in diagnostic testing, reported substantial net revenues of $6.7 billion for the fiscal year ended December 31, 2007. The company processes a vast volume of test requisitions, reflecting its significant market share and operational scale in the U.S. clinical testing industry. Quest Diagnostics' strategy centers on enhancing the patient experience, maintaining high quality through Six Sigma processes, leveraging its extensive network of laboratories and patient service centers, driving medical innovation, expanding its geographic reach, and broadening its diagnostic scope, including through strategic acquisitions. Key areas of focus for growth include gene-based and esoteric testing, which represent a significant portion of revenue and offer higher reimbursement. The company also highlighted its investments in healthcare information technology, such as the Care360 Physician Portal, to improve patient care and clinician efficiency. Despite a competitive landscape and evolving regulatory environment, Quest Diagnostics is positioning itself to capitalize on demographic trends and technological advancements in the healthcare sector.

Financial Highlights

28 data points
Beta

Revenue

$6.70B

40.8% Gross Margin

Net Income

$339.94M

5.1% Net Margin

EPS (Diluted)

$1.74

Cash & Equivalents

$167.59M

Free Cash Flow

$707.82M

Financial Statements
Beta
Revenue$6.70B
Cost of Revenue$3.97B
Gross Profit$2.74B
SG&A Expenses$1.61B
Operating Expenses$5.61B
Operating Income$1.09B
Net Income$339.94M
EPS (Basic)$1.76
EPS (Diluted)$1.74

Key Highlights

  • 1Quest Diagnostics generated $6.7 billion in net revenues for the fiscal year ended December 31, 2007, processing approximately 145 million test requisitions.
  • 2The company's strategy focuses on delivering a superior patient experience, driving quality through Six Sigma, leveraging its extensive national network, leading in medical innovation, expanding geographically, and broadening its diagnostic scope.
  • 3Gene-based and esoteric testing, a high-growth area, accounted for approximately 18% of 2007 net revenues, with the company being a leading provider in the U.S.
  • 4Acquisitions, such as AmeriPath in May 2007, are being utilized to expand capabilities and differentiate the company from competitors.
  • 5Quest Diagnostics is investing in healthcare information technology solutions, including the Care360 Physician Portal, which is used by over 125,000 physicians.
  • 6The company is a leading provider of risk assessment services to the life insurance industry and clinical testing for employers (drug-of-abuse testing).
  • 7The company faces significant competition from hospital-affiliated labs, other commercial labs, and physician office labs, and is actively working to integrate acquired businesses.

Frequently Asked Questions

In 2007, Quest Diagnostics' clinical testing business accounted for over 90% of net revenues. Within clinical testing, routine testing was the largest segment at approximately 55%, followed by gene-based and esoteric testing (18%), and anatomic pathology services (15%).

Quest Diagnostics' key strategic initiatives include delivering a superior patient experience, continuously driving Six Sigma quality, leveraging its extensive asset and capability network, leading in medical innovation and IT solutions, expanding its geographic reach internationally, and expanding its diagnostic scope through new technologies and acquisitions.

Key risks and challenges include intense competition, pricing pressures from payers (government and commercial insurers), potential adverse regulatory actions and investigations (such as the NID matter), difficulties in integrating acquired businesses, reliance on information technology systems, and the evolving landscape of healthcare delivery with potential shifts to point-of-care testing.

Quest Diagnostics is addressing this trend by acquiring companies with point-of-care testing capabilities (e.g., HemoCue, Focus Diagnostics, Enterix) and developing electronic data links to integrate these tests with its existing Care360 system, aiming to offer comprehensive solutions to its customers.